BioStem Technologies has agreed to acquire BioTissue Holdings’ surgical and wound care business, expanding the former company’s existing wound care product range in a deal worth up to $40m.
BioStem will outlay an upfront cash payment of $15m to acquire the Florida-based company’s unit, which includes products such as Neox and Clarix cryopreserved amniotic membrane allografts. The deal includes potential milestone payments of up to $10m for achieving US Food and Drug Administration (FDA) clearance for an unspecified pipeline product, and $15m for additional commercial milestones.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BioTissue’s Neox and Clarix are positioned as complementary products to BioStem’s existing dehydrated amniotic-derived allograft offerings such as the AmnioWrap allograft for chronic and acute wound care. BioStem said the assets will help advance the company’s access to chronic and acute wound care markets in hospital inpatient, outpatient, and ambulatory surgery centre settings.
Neox is designed for chronic and acute wound applications, while Clarix is intended for surgical applications such as tendon repair and nerve protection. The allografts are derived from human amniotic and umbilical cord tissue from consenting donors and cryopreserved using BioTissue’s CryoTek technology that is designed to keep the allograft’s extracellular matrix and bioactive factors intact.
BioStem’s CEO Jason Matuszewski highlighted that acquiring these assets will give the company an “immediate foothold” in hospital-based applications while expanding its existing technology portfolio with an additional platform designed for placental and umbilical tissue allograft preservation.
“This acquired technology opens meaningful entry into high-value adjacent market segments, from acute surgical wounds to burns and soft-tissue repair, while creating synergies that enhance our entire product suite and diversify our revenue streams,” Matuszewski continued.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWound care represents a rapidly advancing market. According to GlobalData analysis, the field is growing at a CAGR of 4.8% and is projected to reach a valuation over $53bn in 2034, up from $33.19bn in 2024.
In November 2025, Solventum acquired US-based Acera Surgical, availing it with the Missouri-based company’s Restrata line of electrospun fibre matrices for wound treatment, in a deal worth up to $850m. The transaction stood as the largest in the broader wound care space since Coloplast’s $1.3bn acquisition of Iceland’s Kerecis, the developer of a wound care technology platform based on intact fish skin, in 2023.
